日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

阿伐替尼±德法替尼治疗复发性低级别浆液性卵巢癌的疗效和安全性:ENGOT-OV60/GOG-3052/RAMP 201研究的主要分析

Banerjee, Susana N; Van Nieuwenhuysen, Els; Aghajanian, Carol; D'Hondt, Véronique; Monk, Bradley J; Clamp, Andrew; Prendergast, Emily; Oaknin, Ana; Ring, Kari; Colombo, Nicoletta; Holloway, Robert W; Rodrigues, Manuel; Chon, Hye Sook; Gourley, Charlie; Santin, Alessandro D; Thaker, Premal H; Gennigens, Christine; Newman, Gregg; Salinas, Erin; Youssoufian, Hagop; Moore, Kathleen N; Lustgarten, Stephanie; O'Malley, David M; Van Gorp, Toon; Grisham, Rachel N

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer

泛亚洲版ESMO临床实践指南,用于管理新诊断和复发性上皮性卵巢癌患者

Nag, S; Ray Coquard, I; Gupta, S; Pathak, A; Li, N; Mulya Sari, R; Harano, K; Kim, G M; Ang, S F; Que, F V; Chay, W Y; Lai, H-C; Ativitavas, T; Tangjitgamol, S; Lai, C-H; Heong, V Y M; Contreras Tolentino, J; Ngu, M R; Yun, J; Yunokawa, M; Hanafi, W L H; Li, J; Smyth, E; Yoshino, T; Mehta, J; Pentheroudakis, G; Maheshwari, A; Cervantes, A; Basade, M; Oaknin, A

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial

Rucaparib用于铂敏感复发性卵巢癌维持治疗:3期随机、安慰剂对照ARIEL3试验的最终结果

Ledermann, Jonathan A; Oza, Amit M; Lorusso, Domenica; Aghajanian, Carol; Oaknin, Ana; Dean, Andrew; Colombo, Nicoletta; Weberpals, Johanne I; Clamp, Andrew R; Scambia, Giovanni; Leary, Alexandra; Holloway, Robert W; Gancedo, Margarita Amenedo; Fong, Peter C; Goh, Jeffrey C; O'Malley, David M; Armstrong, Deborah K; Banerjee, Susana; García-Donas, Jesús; Swisher, Elizabeth M; Lebreton, Coriolan; Konecny, Gottfried E; McNeish, Iain A; Scott, Clare L; Maloney, Lara; Goble, Sandra; Lin, Kevin K; Coleman, Robert L

Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

研究总结:曲妥珠单抗德鲁替康治疗HER2表达实体瘤的疗效(按入组HER2 IHC状态划分):DESTINY-PanTumor02研究的事后分析

Oaknin, Ana; Lee, Jung-Yun; Makker, Vicky; Oh, Do-Youn; Banerjee, Susana; González-Martín, Antonio; Jung, Kyung Hae; Ługowska, Iwona; Manso, Luis; Manzano, Aránzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Fielding, Anitra; Puvvada, Soham; Smith, Ann; Meric-Bernstam, Funda

Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc

阿特珠单抗、贝伐珠单抗和铂类化疗治疗宫颈癌:BEATcc 研究日本人群的结果

Takekuma, Munetaka; Nishio, Shin; Yamaguchi, Satoshi; Yunokawa, Mayu; Nishio, Hiroshi; Nishino, Koji; Kurosaki, Akira; Minobe, Shinichiro; Villacampa, Guillermo; Oaknin, Ana; Okamoto, Aikou

Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY

RUBY研究第一部分:多斯利单抗在原发性、晚期或复发性子宫内膜癌中的群体药代动力学和暴露-反应关系

Kuchimanchi, Mita; Jørgensen, Trine Lembrecht; Hanze, Eva; André, Thierry; Jain, Angela; Berton, Dominique; Alskär, Oskar; Zub, Oleksandr; Oaknin, Ana; Shahin, Mark S; Koliadi, Anthoula; Pothuri, Bhavana; Krivak, Tom; Pishchyk, Mikalai; Segev, Yakir; Backes, Floor J; Gennigens, Christine; Bouberhan, Sara; Zajic, Stefan; Melhem, Murad; Buscema, Joseph

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201

阿伐替尼联合法伐替尼治疗复发性低级别浆液性卵巢癌:ENGOT-OV60/GOG-3052/RAMP 201 II期临床试验的简明摘要

Banerjee, Susana N; Van Nieuwenhuysen, Els; Aghajanian, Carol; D'Hondt, Véronique; Monk, Bradley J; Clamp, Andrew; Prendergast, Emily; Oaknin, Ana; Ring, Kari; Colombo, Nicoletta; Holloway, Robert W; Rodrigues, Manuel; Chon, Hye Sook; Gourley, Charlie; Santin, Alessandro D; Thaker, Premal H; Gennigens, Christine; Newman, Gregg; Salinas, Erin; Youssoufian, Hagop; Moore, Kathleen N; Lustgarten, Stephanie; O'Malley, David M; Van Gorp, Toon; Grisham, Rachel N

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

曲妥珠单抗德鲁替康治疗HER2表达实体瘤患者的疗效和安全性:DESTINY-PanTumor02 II期试验的主要结果

Meric-Bernstam, Funda; Makker, Vicky; Oaknin, Ana; Oh, Do-Youn; Banerjee, Susana; González-Martín, Antonio; Jung, Kyung Hae; Ługowska, Iwona; Manso, Luis; Manzano, Aránzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Fielding, Anitra; Ma, Yan; Puvvada, Soham; Shire, Norah; Lee, Jung-Yun

Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial

Bintrafusp Alfa 用于铂类化疗失败后复发或转移性宫颈癌:一项非随机对照试验

Birrer, Michael; Li, Guiling; Yunokawa, Mayu; Lee, Jung-Yun; Kim, Byoung Gie; Oppermann, Christina Pimentel; Zhou, Qi; Nishio, Shin; Okamoto, Aikou; Wu, Xiaohua; Mileshkin, Linda; Oaknin, Ana; Ray-Coquard, Isabelle; Hasegawa, Kosei; Jehl, Genevieve; Vugmeyster, Yulia; Zhang, Sen; Bajars, Marcis; Yonemori, Kan

Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

开发预测住院癌症患者90天死亡率的预后模型(PROMISE工具):一项前瞻性观察研究

Mirallas, Oriol; Martin-Cullell, Berta; Navarro, Víctor; Vega, Kreina Sharela; Recuero-Borau, Jordi; Gómez-Puerto, Diego; López-Valbuena, Daniel; Salva de Torres, Clara; Andurell, Laura; Pedrola, Anna; Berché, Roger; Palmas, Fiorella; Ucha, José María; Villacampa, Guillermo; Rezqallah, Alejandra; Sanz-Beltran, Judit; Bach, Rafael; Bueno, Sergio; Viaplana, Cristina; Molina, Gaspar; Hernando-Calvo, Alberto; Aguilar-Company, Juan; Roca, María; Muñoz-Couselo, Eva; Martínez-Martí, Alex; Alonso, Ada; Eremiev, Simeon; Macarulla, Teresa; Oaknin, Ana; Saura, Cristina; Élez, Elena; Felip, Enriqueta; Peñuelas, Ángeles; Burgos, Rosa; Pardo, Patricia Gómez; Garralda, Elena; Tabernero, Josep; Serradell, Sònia; Servitja, Sònia; Paez, David; Dienstmann, Rodrigo; Carles, Joan